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Abstract 
Purpose: To synthesize and characterize novel hydroquinone compounds that exhibit an aspirin-like 
pharmacological profile devoid of ulcerogenic side effects. 
Methods: Two novel hydroquinone derivatives, viz, 2,5-bis(piperidinomethyl)hydroquinone and 2,5-
bis(pyrrolidinomethyl)hydroquinone, were synthesized by refluxing hydroquinone, paraformaldehyde 
and secondary amines (piperidine or pyrrolidine) in ethanol. The structures were authenticated by 
infrared (IR) spectroscopy, elemental analysis, mass spectrometry (MS) and 1H and 13C nuclear 
magnetic resonance (NMR) spectroscopic techniques. The synthesized derivatives were evaluated for 
antinociceptive, anti-inflammatory and antipyretic activities along with gastric-ulcerogenicity using well-
known testing paradigms. Aspirin served as reference standard. 
Results: The newly synthesized hydroquinone derivatives, significantly attenuated tonic visceral 
chemically-induced nociception at 10 mg/kg (p < 0.01, p < 0.001), 20 and 40 mg/kg (p < 0.001), 
inhibited the temporal-inflammatory reaction at 50 mg/kg (2 - 5 h, p < 0.05, p < 0.001), 100 and 150 
mg/kg (1 - 5 h, p < 0.05, p < 0.01, p < 0.001) in addition to alleviating the febrile-response at test doses 
during 0.5 h (p < 0.05, p < 0.01, p < 0.001), 1 and 1.5 h (p < 0.001) of the study period. The synthesized 
compounds exhibited improved gastric tolerability profile since they were devoid of aspirin-associated 
biochemical and ulcerative changes. The in silico studies predicted high binding affinity of the 
hydroquinone derivatives to the active site of the cyclooxygenase 2 (COX-2) enzyme. 
Conclusion: The synthesized hydroquinone compounds possess analgesic, antipyretic and anti-
inflammatory properties with low gastric-ulcerogenic potential. This may be credited to preferential 
inhibition of the COX-2 enzyme and the beneficial basic rather than acidic chemical nature of the 
compounds. However, further molecular studies are required to substantiate these findings. 
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Non-steroidal anti-inflammatory drugs (NSAIDs) 
are classic therapeutic agents used 
predominantly  for inflammation, pyrexia and mild 
to moderate pain [1]. However, their clinical 
usefulness is limited by accompanying side 
effects, which include gastric ulceration, bleeding 
from the gastrointestinal tract, cardiovascular 
problems and renal complications [2,3]. This is a 
major restraint on the remedial application of 
NSAIDs. Therefore, there is a need for 
therapeutic compounds that are efficacious in 
alleviating inflammation, pain and pyrexia, while 
exhibiting fewer gastrointestinal side effects.   
 
Hydroquinone or benzene-1,4-diol may be 
obtained by hydrolysis of arbutin (Figure 1A) 
using the enzyme, β-glucosidase [4]. Arbutin is a 
glycoside of hydroquinone which may be 
extracted from the leaves of bearberry, 
Arctostaphylos uvaursi [5]. It has anti-
inflammatory and anti-tyrosinase activities, and is 
devoid of any gastric toxicity [6,7]. In this respect, 
hydroquinone has anti-inflammatory properties 
which are mediated through inhibition of 
proinflammatory cytokines (TNF-α, IL-1β, IL-6) or 
via release of toxic substances like nitric oxide 
(NO) [8]. The hydroquinone ring structure is very 
interesting because it lends itself to many 
pharmacologically active moieties. For example, 
acetaminophen, a well-known analgesic, has 
been synthesized by substitution in the 
hydroquinone structure [9]. 
The compounds reported in our study, viz, 2,5-
bis(piperidinomethyl)hydroquinone (compound 
(1)) and 2,5-bis(pyrrolidinomethyl)hydroquinone 
(compound (2)) are derived from hydroquinone 
ring substitution, via integration of 
pharmacologically important piperidine and 
pyrrolidine heterocyclic moieties. It has been 
reported that chemical compounds containing 
these moieties possess diverse pharmacological 
properties including antinociceptive, anti-
inflammatory and antipyretic activities [10,11]. 
Similarly, pyrrolidine ring-containing compounds 
have been shown to be effective against various 
disease conditions such as migraine, bipolar 
disorders, tuberculosis and cancer [12,13]. In this 
connection, piperidine and pyrrolidine 
heterocycles are considered as critical nuclei for 
novel drug design. These moieties associated 
with diverse pharmacological activities 
encouraged us to incorporate them into the basic 
hydroquinone structure. Therefore, hydroquinone 
derivatives were synthesized and their structures 
were confirmed by different spectroscopic 
methods (IR, 1H-NMR, 13C-NMR, mass 
spectrometry and elemental analysis) and were 
then evaluated for antinociceptive, antipyretic 
and anti-inflammatory activities as well as any 
gastro-ulcerogenic proclivity, using in vivo testing 
paradigms. Additionally, the binding affinity of 
these compounds with cyclooxygenase (COX) 
enzymes (COX-1 and COX-2) was studied using 




Figure 1: Chemical structures of hydroquinone (A), 




Instruments and apparatus 
 
A Nicolet 380 thermoscientific FTIR (USA) 
instrument was used for recording Infrared (IR) 
spectra. 1H and 13C-NMR analyses (Bruker 
AVANCE 400 MHz, Germany) were conducted 
using DMSO-d6 or D2O as solvents. Mass 
spectra (ESI-MS) were obtained on a Bruker 
micrOTOF II (USA) mass spectrometer. 
Elemental analyses were performed on an 
Elementar Analysensysteme (GmbH VarioEL 
V4.01 20.Aug. 2002 (Germany) instrument 
operated in CHN mode. Histological slides were 
prepared with the help of a microtome (SLEE 
MAINZ, Germany). 
 
Synthesis of hydroquinone derivatives 
 
Hydroquinone derivatives were prepared by a 
simple reaction between secondary amine, 
paraformaldehyde and hydroquinone. While 
synthesizing these derivatives, quinone was 
amino methylated according to a known method 
[14] as given in Scheme 1. The synthesized 
compounds were obtained in a good yield. 
 
Compound 1 (2,5-bis(piperidinomethyl) 
hydroquinone) 
 
Piperidine (20 mmol, 1.96 mL) and 
paraformaldehyde (33.3 mmol, 1 g) were slowly 
mixed and then refluxed for 1 h to obtain a clear 
solution. The resulting solution was cooled to 
room temperature (25 0C) and a solution of 
hydroquinone (10 mmol, 1.1 g) in ethanol (100 
mL) was added to the above mixture. The 
mixture was stirred using a magnetic stirrer and 
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Scheme 1: Synthetic route for compounds 1 and 2 
 
was monitored by taking samples for TLC at 1 h 
interval. The reaction was completed after 8 
hours.  After removal of solvent at ambient 
temperature, a brownish solid was obtained 
which was recrystallized three times with ethanol 
to obtain pure white crystals (Figure 1C). 
 
Compound 2 (2,5-bis(pyrrolidinomethyl) 
hydroquinone) 
 
A mixture of hydroquinone (10 mmol, 1.1 g), 
pyrrolidine (20 mmol, 1.64 mL) and 
paraformaldehyde (33.3 mmol, 1 g) was refluxed 
in ethanol (100 mL) for 20 h. The resulting 
solution was cooled to room temperature (25 oC) 
and filtered to obtain a brownish solid. The solid 
was recrystallized three times with ethanol in 
order to remove any entrapped impurity and to 





BALB/c mice and Sprague–Dawley rats of either 
sex were used and housed separately as 6 
animals per cage, under laboratory conditions of 
22 ± 2 °C, 40 - 60 % relative humidity (RH) and 
12 h light/12 h dark cycle. The experimental 
animals were provided free access to food and 
water and were kept under the standard 
laboratory conditions in the animal housing 
facility established at Department of Pharmacy, 
University of Peshawar, Pakistan. Prior to 
commencement of the experiments, animals 
were allowed to habituate for 2 h to the 
laboratory conditions. The experimental 
procedures reported below were approved by the 
Institutional Animals Ethics Committee with 
registration no. 11/ EC-15/Pharm and performed 
in compliance with the UK approved guidelines 
for laboratory animals [15]. 
Acute toxicity test 
 
Mice (25-30 g, n = 6) were administered with test 
compounds intraperitoneally (i.p.) at 50, 100, 250 
and 500 mg/kg. Morbidity was observed 
continuously for the first 2 h, while mortality up to 
24 h after dose administration. The animals were 
observed for impulsive activity,  cyanosis, 
convulsions, catalepsy, contortions, tail pinch 
response, and abnormal behavior [16]. 
 
Determination of antinociceptive activity 
 
Acetic acid-induced abdominal constriction 
assay 
 
BALB/c mice (18-22 g, n = 6) were randomly 
divided into ten groups. Group I was 
administered normal saline (i.p.). Group II-IV 
received standard aspirin at 10, 20 and 40 mg/kg 
(i.p.), respectively. Similarly, groups V-VII 
received compound (1) and groups VIII-X 
received compound (2) at 10, 20 and 40 mg/kg 
(i.p.), respectively. Thirty min after treatment, 1 % 
acetic acid (i.p.) was injected and after a further 5 
min, abdominal constrictions (writhes) for each 
group were determined and the behavior was 
observed for 20 min [17]. Percentage protection 
(PP) was calculated as in Eq 1. 
 
PP = {(1 – Mt/Mc)}100 …………………… (1) 
 
where Mt and Mc represented mean number of 
abdominal constrictions of the treated drug and 
the control group, respectively. 
 
Hot plate assay 
 
BALB/c mice (18-22 g, n = 6) exhibiting a latency 
< 15 s signified by a hind limb flick, licking or 
jumping, when placed on the hot plate (54.0 ± 
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0.10 oC, Harvard apparatus, USA) were included 
in the study. Animals were administered 
compounds (1) or (2) (10, 20 and 40 mg/kg, i.p.) 
or morphine (5 mg/kg, i.p.) and 30 min after each 
treatment, response latencies were noted at 30, 
60 and 90 min. To avoid tissue injury, a 30 s cut-
off time was imposed [18]. The percent 
antinociception (PA) was calculated as in Eq 2. 
 
PA = {(Tl – Cl/Ct – Cl)}100……………… (2) 
 
where Tl, Cl and Ct represented test latency, 
control latency and cut-off time, respectively. 
 
Carrageenan induced inflammatory assay 
 
BALB/c mice (25 - 30 g, n = 6) were divided into 
ten groups in carrageenan-induced inflammatory 
assay. Group I received normal saline (i.p.). 
Groups II - IV received standard aspirin at 50, 
100 and 150 mg/kg (i.p.), respectively. Similarly, 
groups V - VII received compound (1) and 
groups VIII-X received compound (2) at 50, 100 
and 150 mg/kg (i.p.), respectively. One hour after 
treatment, each group received 1 % carrageenan 
suspension, injected subcutaneously (s.c) into 
the planter region of the rear paw. Mean paw 
swelling was measured using a digital 
plethysmometer (Model LE 7500 Plan lab S.L, 
Italy) before carrageenan administration and 
thereafter at1 h intervals for 5 h [19]. Inhibition of 
edema (H) was calculated as in Eq 3. 
 
H (%) = {(A – B)/A}100 ……………… (3) 
 
where A is the mean paw volume of control and 
B represented the mean paw edema volume of 
the test group. 
 
Brewer’s yeast induced pyrexia assay 
 
BALB/c mice (25 - 30 g) were divided into ten 
different groups of six animals per group. All 
animals were deprived of food with free access 
to water. The baseline rectal temperature of all 
mice was noted by inserting a lubricated digital 
thermometer probe (model CA92121, ACON 
Laboratories, USA) into the rectum (to a depth of 
2 cm) of each animal and then pyrexia was 
induced using a suspension of 20 % Brewer’s 
yeast (Merck, Germany, 10 mL/kg) by the 
subcutaneous route.  
 
Any change in the rectal temperature of each 
animal was measured 24 h after Brewer’s yeast 
administration and those animals which 
expressed a rise of 0.3 to 0.5 oC were selected 
for the study [20]. Group I was treated with 
normal saline (i.p.). Groups II - IV received 
aspirin (50, 100 and 150 mg/kg, i.p, respectively), 
groups V-VII received compound (1) while the 
remaining groups (VIII - X) received compound 
(2) at doses of 50, 100 and 150 mg/kg, i.p., 
respectively.  Following drug administration, the 
rectal temperature of each mouse was measured 
at 0.5, 1 and 1.5 h. The mean decrease in rectal 
temperature across treated groups was 
compared relative to untreated controls. 
 
Assessment of gastric ulcerogenicity 
 
Sprague-Dawley rats (150 - 200 g, n = 6) were 
randomly divide to treatment groups and each 
animal was administered the following treatment 
once a day orally for 6 days as follows: 
 
Group I – normal  saline 
Group II – aspirin (150 mg/kg) 
Groups III – compound (1) (100 mg/kg)  
Groups IV – compound (1) (150 mg/kg) 
Groups V – compound (2) (100 mg/kg) 
Group VI – compound (2) (150 mg/kg). 
 
The last dose for each animal group was 
administered 1 h prior to pyloric ligation. At the 
end of the protocol, each rat was killed and the 
stomach mucosa was removed. The 
macroscopic injury was observed with 10x lens 
and ulcer severity was scored [21]. The gastric 
content was also collected and centrifuged for 10 
min at 1,000 rpm and the supernatant was taken 
apart. The volume (ml), pH, free acidity, total 
acidity and pepsin concentration of the gastric 
juice were determined using the procedures 
reported previously in our laboratory [22]. After 
centrifugation, the gastric juice volume was 
measured with a pipette and pH was determined 
with a digital pH meter. For determination of free 
acidity, 1 mL of supernatant was mixed with 2 – 3 
drops of Toper’s reagent and was titrated against 
0.01 N NaOH.  
 
The changes in the color of solution from light 
red to canary yellow determined the free acidity. 
To this solution, two drops of phenolphthalein 
indicator were added and the titration process 
was continued until the appearance of 
permanent a pink color. The volume (mL) of 
alkali utilized was noted and this represented the 
total acidity. For pepsin activity determination, 
the absorbance of protein was measured at 700 
nm and the results were presented as 
micromoles of tyrosine liberated per mL. 
 
Assessment of histopathological changes 
 
At the end of each experiment, the stomach 
specimens were fixed immediately in formalin (10 
% neutrally buffered) for 48 h, dehydrated in 
variant ethanol (50–100 %) solutions, cleared in 
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100 % xylene and immersed in paraffin. Sections 
(5 µm thickness) were cleared, hydrated and 
then stained (hematoxylin and eosin) [23]. The 
prepared slides were evaluated for any 
histopathological changes. 
 
In silico studies 
 
The structures of cyclooxygenase-1 (COX-1) with 
bound Flurbiprofen (PDB ID 1CQE) and 
cyclooxygenase-2 (COX-2) enzyme with bound 
selective inhibitor (PDB ID 1CX2) were 
downloaded from the website 
(www.rcsb.org/pdb) of the Protein Data Bank 
(PDB) and the binding site residues of the 
receptors were identified. Bound ligands were 
then removed from the receptor binding site 
using discovery studio 4.0 (Dassault Systèmes 
BIOVIA, Discovery Studio Modeling 
Environment, Release 2017, San Diego: 
Dassault Systèmes, 2016).  
 
The enzyme and ligand structures were then 
prepared for docking using Autodock Tools. The 
study ligands namely 2,5-bis(piperidinomethyl) 
hydroquinone (compound 1) and 2,5-bis 
(pyrrolidinomethyl)hydroquinone (compound 2)  
were then docked into the binding site of COX 
active sites using Autodock Vina [24]. Nine 
binding modes were proposed by the program 
and the binding mode with lowest binding energy 





Statistical significance of pharmacological data 
was determined using one-way ANOVA followed 
by post hoc Dunnett’s test. P < 0.05 level was 
considered as significant. Data are expressed as 




Spectral characteristics of synthesized 
molecules 
 
Compound 1 (2,5-bis(piperidinomethyl) 
hydroquinone) 
 
White crystals; Yield: 56.0 %, m.p. 189.0 0C. IR 
(KBr) vmax: 3853, 2945, 1452, 1377, 1307, 1107, 
988, 879, 787 cm-1. 1H NMR (400 MHz, DMSO-
d6) δ 2.39 (t, 8H, H7, 7’, 11, 11’), 1.42-1.51 (m, 12H, 
H8, 8’, 9, 9’, 10, 10’), 3.49 (s, 4H, Hi, i’), 10.16 (s, 2H, 
Hh, h’), 6.41 (s, 2H, H3, 6). 13C NMR (75 MHz, D2O) 
δ 24.08 (2C, C9, 9’), 25.94 (4C, C8, 8’, 10, 10’), 53.74 
(4C, C7, 7’, 11, 11’), 60.43 (2C, Ci, i’), 115.92 (2C, C3, 
6), 121.82 (2C, C2, 5), 149.61 (2C, C1, 4). HRMS 
(ESI): calcd for C18H28N2O2 305.221: [M + H]+, 
found: 305.224. Anal. Calcd. for C18H28N2O2: C, 
71.02; H, 9.27; N, 9.20. Found: C, 70.90; H, 
10.37; N, 9.38. 
 
Compound 2 (2,5-bis(pyrrolidinomethyl) 
hydroquinone) 
 
White crystals; Yield: 55.5 %, m.p. 153.8 0C. IR 
(KBr) vmax: 3848, 2801, 1480, 1389, 1307, 1198, 
888, 833 cm-1. 1H NMR (400 MHz, DMSO-d6) δ 
2.48-2.49 (t, 8H, H7, 7’, 10, 10’), 1.72-1.76 (m, 8H, 
H8, 8’, 9, 9’), 3.61 (s, 4H, H i, i’), 9.93 (s, 2H, Hh, h’), 
6.46 (s, 2H, H3, 6). 13C NMR (75 MHz, D2O) δ 
23.60 (4C, C8, 8’, 9, 9’), 53.54 (4C, C7, 7’, 10, 10’), 
56.78 (2C, C i, i’), 115.47 (2C, C3, 6), 122.88 (2C, 
C2, 5), 149.23 (2C, C1, 4). HRMS (ESI): calcd for 
C16H24N2O2 277.188: [M + H]+, found: 277.191. 
Anal. Calcd. for C16H24N2O2: C, 69.53; H, 8.75; 




Both compounds did not reveal any behavioral 
changes or mortality at doses up to 500 mg/kg. 
 
Compounds (1) and (2) attenuated tonic 
visceral nociception 
 
As shown in Figure 2, a significant attenuation of 
tonic visceral nociception was produced by 
aspirin at doses of 10 mg/kg (p < 0.01), 20 and 
40 mg/kg (p < 0.001) and also the head to head 
doses of compound (1) (p < 0.001) in the acetic 
acid-induced abdominal constrictions assay. 
Likewise, compound (2) also afforded maximum 
protection against nociceptive behavior at the 
tested doses of 10 mg/kg (p < 0.01), 20 and 40 
mg/kg (p < 0.001). In the hot plate test, both 




Figure 2: Antinociceptive effect of aspirin, compounds 
1 and 2, at 10, 20 and 40 mg/kg (i.p.). Values are 
percent inhibition of abdominal constrictions ± SEM (n 
= 6); **p < 0.01, ***p < 0.001 as compared to saline 
treated control; n = 6  
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doses against acute phasic nociception, 
however, in comparison morphine (5 mg/kg) 
provided significant protection against thermal 
hyperalgesia after 30, 60 min (p < 0.001) and 90 




Figure 3: Antinociceptive effect of (A) compound 1, 
and (B) compound 2, at 10, 20, 40 mg/kg (i.p.) in the 
hot plate assay. Values are percent response 
latencies ± SEM of 6 mice per group; **p < 0.01, ***p < 
0.001 as compared to saline treated control 
 
Compounds (1) and (2) alleviated temporal 
inflammatory response 
 
After 1 h, a significant reduction in paw swelling 
was observed in response to doses of 100 and 
150 mg/kg of aspirin (p < 0.05), compound (1) 
(p< 0.05) and compound (2) (p < 0.01, p< 0.001). 
After 2 h, all the test doses (50 mg/kg, p< 0.05; 
100 and 150 mg/kg; p < 0.01) of aspirin and 
compound (1) downgraded the inflammatory 
response. These doses of aspirin as well as 
compound (1) were more effective during the late 
phase of inflammation, where a significant 
diminution of the swelled paw was observed at 3 
h (p < 0.05, p < 0.01) and 4-5 h (p < 0.001). 
Compound (2) was more effective (p < 0.001) in 
decreasing the edema induced by the phlogistic 
agent and was able to counteract both early and 
late phases of inflammation (Figure 4). 
 
Compounds (1) and (2) suppressed yeast-
induced pyrexia 
 
As shown in Figure 5, after 0.5 h, a significant 
decrease in the Brewer’s yeast induced febrile 
response was observed in response to aspirin, 
compounds (1) and (2) at the tested doses of 50 
mg/kg (p < 0.05, p < 0.01), 100 mg/kg (p < 0.01, 
p < 0.001) and 150 mg/kg (p < 0.001). As time 
progressed, the reduction in body temperature 
become even more highly significant and  the 
antipyretic effect was even more marked after 1 
and 1.5 h for aspirin, compounds (1) and (2), 
when evaluated at doses of 50, 100 mg/kg (p < 





Figure 4: Anti-inflammatory effect of (A) aspirin, (B) 
compound 1 and (C) compound 2, at 50, 100 and 150 
mg/kg (i.p.). Values are mean paw volume in mL ± 
SEM (n = 6); *p < 0.05, **p < 0.01, ***p < 0.001 as 
compared to saline treated control 
 
 
Figure 5: Antipyretic effect of aspirin, compounds 1 
and 2, at 50, 100 and 150 mg/kg (i.p.). Values are 
mean rectal temperature in 0C, ± SEM (n = 6); *p < 
0.05, **p < 0.01, ***p < 0.001 as compared to saline 
treated control 
 
Compounds (1) and (2) were devoid of 
gastric-ulcerogenicity 
 
Figure 6A depicted the dose of 150 mg/kg of 
aspirin per day for a period of 6 consecutive days 
and it significantly increased the ulcer score (F5,30 
= 7.79, p < 0.001), the volume of gastric juice 
(F5,30 = 10.64, p < 0.001, Figure 6B), gastric pH 
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(F5,30 = 5.47, p < 0.01, Figure 6C), free acidity 
(F5,30 = 5.75, p < 0.001, Figure 6D) and total 
acidity (F5,30 = 6.56, p < 0.001, Figure 6E), when 
compared to control. However, these parameters 
were unchanged with the tested compounds at 
100 and 150 mg/kg, and they were comparable 
to that of control animals. Moreover, the pepsin 
concentration was not affected in any of the 
treatment groups (Figure 6F). 
 
Examination of gastric mucosa (photomicro-
graphs) revealed an absence of morphological 
changes (hemorrhagic streaks or spot ulcers) in 
the stomach mucosa of animal groups treated 
with compounds (1) and (2) and saline. 
Nonetheless, visually noticeable changes were 
perceived in the mucosa of aspirin-treated group 
(Figure 7A - F). 
 
 
Figure 6: Ulcerogenicity of aspirin (150 mg/kg), 
compound 1 and compound 2 (100, 150 mg/kg). Each 
bar represents (A) ulcer score, (B) gastric juice 
volume, (C) gastric pH, (D) free acidity, (E) total 
acidity, and (F) pepsin concentration ± SEM (n = 6); 
**p ˂ 0.01, ***p ˂ 0.001, compared to saline control 
 
Using light microscopy, the gastric mucosa of 
control rats revealed normal histo-architecture 
with undamaged structures and normal epithelial 
lining (Figure 7A1). The gastric mucosa of aspirin 
treated rats showed damaged mucosal 
epithelium, submucosal edema and inflammation 
at the ulcer site (Figure 7B1); whereas, rats 
administered compound 1 (100, 150 mg/kg, 
Figure 7C1 and D1) and compound 2 (100, 150 
mg/kg, Figure 7E1 and F1) exhibited no 
ulceration, and the histological appearance was 




Figure 7: Gross appearance of stomach mucosa from 
groups of animals treated with (A) saline control rats; 
(B) aspirin treated rats showing ulcer spots and 
bleeding; (C) compound 1 (100 mg/kg) treated rats; 
(D) compound 1 (150 mg/kg) treated rats; (E) 
compound 2 (100 mg/kg) treated rats, and (F) 
compound 2 (150 mg/kg) treated rat, which were 
essentially devoid of ulcers. Sections of gastric 
mucosa of control and experimental animals were 
stained by employing hematoxylin and eosin and were 
observed under light microscopy. (A1) The control 
group exhibited normal structure of the epithelial lining 
(arrowed). (B1) The aspirin (150 mg/kg) treated group  
displayed disruption and erosion of mucosa (large 
arrow), infiltration of red blood cells and lymphocytes 
in the submucosa (asterisk) along with necrotic debris 
visible in the lumen (small arrow) of the ulcer,  while a 
normal gastric epithelial lining (arrows) was observed 
for (C1) compound 1 (100 mg/kg), (D1) compound 1 
(150 mg/kg), (E1) compound 2 (100 mg/kg) and (F1) 
compound 2 (150 mg/kg) which are similar to that of 
control. Magnification: 10x 
 
Compounds (1) and (2) exhibited an 
antagonistic tendency against COX enzymes 
 
The active sites of both isoforms of COX were 
predominantly hydrophobic except for the Arg120 
residue. The active site binding mechanism of 
NSAIDS to the COX isoforms involved extensive 
non-covalent pi-interactions, in addition to the 
charged interactions of the ionized carboxylic 
group of the NSAID with the protonated arginine 
side chain. 
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The results of our docking study show that 
aspirin (2-Acetoxy Benzoic Acid) binds both of 
the cyclooxygenase isoforms. Aspirin was 
present near a Serine residue (SER 530) of the 
cyclooxygenase-2 enzyme, which is located 
outside the active site of the enzyme (Figure 8C). 
Aspirin is known to act through acetylation of this 
serine residue by the transfer of its own acetyl 
group. Our docking results predict binding of 
aspirin to SER 530 of both cyclooxygenase 
isoforms through the same mechanism. On other 
hand, compounds (1) and (2) showed higher 
affinity to the COX-2 isoform mainly due to H-
bonding with this enzyme. The most favourable 
binding modes of compounds (1) (Figure 8A) and 
compound (2) (Figure 8B) showed H-bonding of 
the hydroxyl groups on the hydroquinone nucleus 
with the histidine residue (His 90 in compound 1) 
and tyrosine and arginine residues (Tyr 355 and 
ARG 120 in compound 2). 
 
Compounds (1) and (2) were docked in the cavity 
of COX-1 enzyme. The binding to COX-1 is 
mainly of hydrophobic nature and binding energy 
to this enzyme is considerably higher as 
compared to the COX-2 isoform. Predictive in-
silico modelling divulged an absence of charged 
interactions between the molecules and the 
enzyme. However, an extensive hydrophobic 




Figure 8: (A) Compound 1 in the cavity of COX-2. H-
bond is represented by a green discontinuous line. Pi-
alkyl and Pi-Pi interactions are represented by grey 
discontinuous lines. (B) Compound 2 shows both H-
bonding and hydrophobic interactions with the active 
site of COX-2. Some of the surface is removed to 
show the binding mode of the compound clearly. H-
bond is represented by green discontinuous line. Pi-
alkyl and Pi-Pi interactions are represented by grey 
discontinuous lines). (C) Aspirin in the vicinity of SER 
530 of COX-2. The acetyl group of Aspirin can be 





The therapeutic utility of non-steroidal anti-
inflammatory drugs (NSAIDs), especially such a 
well-established agent as aspirin is greatly 
hampered by a propensity to induce 
gastrointestinal tract (GIT) insult, particularly 
gastric ulceration [25]. Consequently, over the 
years, extensive research studies have been 
conducted in order to discover synthetic 
substitutes for NSAIDs free from ulcerogenic 
potential. The pharmacological activities of 
NSAIDs mainly derive from inhibition of 
cyclooxygenase (COX) enzymes (COX-1 and 
COX-2) [26]. Thus, nonselective blockade of 
COX enzymes by NSAIDs results in inhibition of 
not only prostaglandins that are induced in 
response to different inflammatory mediators, but 
also those which play an important role in normal 
physiological functions such as mucosal 
protection. Moreover, due to the acidic nature of 
classical NSAIDs, they produce localized erosion 
of the stomach mucosa [27]. Arising from these 
reasons, the excessive use of NSAIDs is linked 
with GIT adverse events and is mostly restricted. 
 
To overcome the problems of NSAIDs, therefore 
we need better alternatives that not only have 
anti-inflammatory, antipyretic and antinociceptive 
properties but are also free from the side-effects 
that are commonly encountered with chronic use 
of NSAIDs. In this study, novel hydroquinone 
derivatives containing piperidine and pyrrolidine 
motifs were synthesized and assessed for 
antinociceptive, anti-inflammatory and antipyretic 
activities as well as their potential for ulcerogenic 
toxicity. The rationale for incorporating piperidine 
and pyrrolidine heterocycles into the 
hydroquinone structure was based on 
observations that these moiety containing 
compounds, when studied previously for 
ulcerogenic activity, they lacked the potential for 
instigating detectable ulcerogenicity [22,28]. 
 
NSAIDs in general, but aspirin in particular, at 
one time, formed a basis for the management of 
moderate pain. In this respect, we compared the 
analgesic effect of our synthesized compounds 
with that of aspirin in the acetic acid induced 
abdominal constriction model of pain, which is 
commonly used for evaluating peripheral 
antinociceptive activity [29]. Pain is induced 
peripherally by the release of a variety of 
endogenous substances particularly mediators 
such as prostaglandins via the action of COX-1 
and its isoform, COX-2 [30]. Additionally, local 
peritoneal nociceptive receptors are very much 
implicated in the abdominal constriction response 
[31]. Consequently, the current test compounds 
exhibited marked inhibitory activity on this 
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nociceptive reaction suggesting the involvement 
of a peripheral analgesic effect which may well 
have been mediated via COX enzymes inhibition 
and/or local peritoneal nociceptors. In contrast, 
the hot plate test involves a spinal reflex as well 
as a more centrally located component which 
when inhibited, reflects central analgesic activity 
[32]. In our study however, the synthetic 
compounds did not produce a selective inhibition 
of thermal nociception. The findings therefore, 
lend support to the participation only of a 
peripheral antinociceptive effect in both cases. 
 
Inflammation is the body’s complex protective 
response involving tissue impairment caused by 
pathogens, mediators and noxious stimuli 
(chemical or physical) [33]. Therapy of 
inflammatory diseases is mainly based on 
interfering with different mediators that direct the 
host’s response to injury [34]. In the current 
study, the hydroquinone derivatives were tested 
in the carrageenan-induced mouse paw edema 
assay. It is known that carrageenan induced paw 
edema is a tri-phasic event, ascribed to the 
release of different mediators including histamine 
and serotonin (1st phase), bradykinin and 
prostaglandins (2nd and 3rd phase) [35]. The 
extended edema mitigating action (up to 5 h) 
displayed by our novel compounds, might 
conceivably entail an inhibitory element on at 
least these four inflammatory mediators. 
 
Pyrexia occurs due to an elevation of 
prostaglandin levels in the hypothalamus as an 
upshot of increased synthesis of this substance 
mediated by the release of pyrogenic cytokines 
in response to exogenous pyrogens [36]. 
Subcutaneous injection of Brewer’s yeast imparts 
febrile effect and is considered as a classical 
method for the screening of potential antipyretics. 
Inhibition of prostaglandin synthesis via blockade 
of COX enzyme activity can be regarded as a 
possible mechanism of antipyretic action similar 
to that of NSAIDs [37]. Accordingly, the 
antipyretic outcomes are very promising as both 
compounds displayed strong antipyretic activity 
comparable to that of aspirin probably implicating 
prostaglandin inhibition. 
 
The results of the ulcerogenicity evaluation 
revealed that the synthesized compounds 
possessed no propensity to incite gastric 
ulceration as compared to aspirin. Predictably, 
the ulcerative effects, as confirmed from the 
biochemical and histological parameters, were 
exacerbated in aspirin-treated animals. The non-
selective COX enzyme inhibition, as well as 
acidic properties possessed by aspirin, are 
largely responsible for local gastric mucosal 
damage [27,38]. However, no significant 
changes in ulcer conducive conditions were 
observed in the case of the novel compounds 
indicating safe gastric profiles. In addition, the 
molecular docking study signified that both 
compounds disclosed a preferential COX-2 
enzyme inhibitory capability which could possibly 
underlie their lack of ulcerogenic activity. 
Moreover, pH analysis of the test compounds 
revealed that they were basic in nature. This 
property might also play a key role in gastric 
safety because as acidic drugs like aspirin are 
present in an unionized state in the stomach. 
Consequently aspirin readily penetrates the 
gastric mucosa to cause gastric erosion and 
ulceration. Furthermore, the test compounds 
were generally well tolerated in the acute toxicity 
test since no mortality or behavioral discomfort 
was observed in doses up to 500 mg/kg and this 




Novel hydroquinone derivatives functionalized 
with piperidine and pyrrolidine have been 
successfully synthesized. These compounds 
possess potent aspirin-like anti-inflammatory, 
analgesic and antipyretic activities, but they are 
devoid of gastric-ulcerogenicity. The absence of 
gastric toxicity may be due, in part, to preferential 
COX-2 enzyme inhibitory activity and basic 
rather than acidic chemical nature. Thus, the 
synthesized compounds may be superior 
therapeutic candidates for the management of 
pain, pyrexia and inflammation. However, further 
studies at the molecular level are required to 
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